image
Healthcare - Biotechnology - NASDAQ - US
$ 4.955
-8.92 %
$ 110 M
Market Cap
-2.27
P/E
CASH FLOW STATEMENT
-12 M OPERATING CASH FLOW
47.19%
0 INVESTING CASH FLOW
0.00%
-4.22 M FINANCING CASH FLOW
-579.56%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis INmune Bio, Inc.
image
Net Income -30 M
Depreciation & Amortization 29.7 M
Capital Expenditures 0
Stock-Based Compensation 7.37 M
Change in Working Capital 10.4 M
Others 1.92 M
Free Cash Flow -12 M

Cash Flow

Millions
Dec-2023 Dec-2022 Dec-2021 Dec-2020 Dec-2019 Dec-2018 Dec-2017 Dec-2016 Dec-2015
OPERATING CASH FLOW
Net Income (30.0) (27.3) (30.3) (12.1) (7.7) (12.4) (0.8) (0.3) 48.9 K
Depreciation & Amortization 0 0 0 0 0 0 0 0 0
Deferred Income Tax 0 0 0 0 0 0 0 0 0
Stock Based Compensation 7.4 7.1 4.8 3.1 4.1 10.0 0.2 0 0.1
Other Operating Activities 0.2 0.3 0.1 3.2 (1.5) 9.8 (0.1) 50 K 30 K
Change in Working Capital 10.4 (2.9) (3.1) 43.5 K (0.3) 0.4 20.1 K 89.9 K 750
Cash From Operations (12.0) (22.7) (28.5) (8.9) (5.4) (2.1) (0.8) (0.3) 18.1 K
INVESTING CASH FLOW
Capital Expenditures 0 0 (15.0) 0 0 0 100 K 0 0
Other Items 0 0 0 0 0 0 0 0 0
Cash From Investing Activities 0 0 (15.0) 0 0 0 100 K 0 0
FINANCING CASH FLOW
Common Stock Repurchased 0 0 0 (1.0) 0 0 0 0 0
Total Debt Repaid (5.0) 0 15.0 0 0 0 0 0 0
Dividends Paid 0 0 0 0 0 0 0 0 0
Other Financing Activities 0 30 K 1.2 0 0 0 0 0.3 0.1
Cash From Financing Activities (4.2) 0.7 96.4 23.9 12.2 0.9 2.1 0.5 30 K
CHANGE IN CASH
Net Change In Cash (16.3) (22.7) 52.8 15.0 6.8 (1.2) 1.2 0.1 11.9 K
FREE CASH FLOW
Free Cash Flow (12.0) (22.7) (43.5) (8.9) (5.4) (2.1) (0.9) (0.3) 18.1 K